Key Highlights

• RGC shares fell 19.12% intraday to $6.50, reversing much of the prior session's 31.9% surge.

• The stock remains roughly 68% below its May registered-direct offering price of $20.30.

• The U.S. Department of Justice is reportedly investigating trading activity in the company's shares.

• Regencell reported a net loss of $5.3 million and held only $2.4 million in cash in its latest reporting period.

Shares Reverse Sharp Prior-Session Gains

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares tumbled Thursday, reversing much of the prior session's 31.9% surge as investors digested a deepening set of concerns surrounding the company.

Regencell is a Causeway Bay, Hong Kong-based early-stage biotechnology company specializing in the research, development and commercialization of Traditional Chinese Medicine formulations for neurocognitive disorders and degeneration, primarily targeting conditions such as Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.

DOJ Subpoena and Weak Financials Weigh on Sentiment

The stock remains roughly 68% below the $20.30 price from its May registered-direct offering, with shares under continued pressure following reports that the U.S. Department of Justice has subpoenaed information related to trading activity in the company's shares. The company reported a net loss of $5.3 million in its latest reporting period, with only $2.4 million in cash on hand, raising fundamental concerns that compound the legal overhang.

Regencell currently trades at a market capitalization of approximately $3.21 billion, with trading volume well above average as investors continue to reassess the stock following its extraordinary run-up earlier in the year.

Conclusion

The reversal in Regencell shares reflects growing investor concern over the combination of a Department of Justice trading investigation, weak underlying financials and a thin cash position. With the stock remaining highly volatile and well below its offering price, continued scrutiny of the company's fundamentals and legal situation will likely keep shares under pressure.

 

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.